Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia

This report provides summarised updates on adverse events following immunisation (AEFIs) of COVID-19 Vaccines in Malaysia.

To receive the latest issues of MADRAC Bulletin, you may join the NPRA Safety Information Mailing List by emailing details of your name, profession and workplace to fv@npra.gov.my (please put in NPRA Safety Mailing List as the subject of your email) OR filling out the subscription form at https://forms.gle/x7eim2Z99HKVNSsz6.

The summary report is only available in English.

Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 29th October 2021)

Introduction

  • How NPRA collects adverse event reports?
  • How NPRA processes AEFI reports and monitors safety of COVID-19 vaccines?

Total Doses of Covid-19 Vaccine Administered

Rate of Reported Adverse Events

  • AEFI responses received via MySejahtera Application
  • AEFI reports received via NPRA Reporting System

Summary

  • Protective benefits of COVID-19 vaccination outweigh the potential risks
Image

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti (Jalan Profesor Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Wednesday 19 January 2022, 16:53:17.
© Copyright 2022 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Search

Main Menu English

Choose Your Language